This post was originally published on this siteThe drug’s protective effects were seen across all the types of questions on an ALS rating scale, but the most sensitive categories appeared

This post was originally published on this siteThough enrollment in a long-term phase 3 study was paused this year due to the pandemic, a new pooled analysis of two trials showed consistent

This post was originally published on this siteNovartis’ asciminib has outperformed Pfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) study, moving it closer to winning

This post was originally published on this siteEarlier this month, the FDA published a list of publicly available social media posts related to certain Essure plaintiffs, which Bayer is required

This post was originally published on this siteThe FDA has rejected Gilead’s filing for approval of filgotinib in rheumatoid arthritis. With the FDA asking to see data from an ongoing

This post was originally published on this siteRoche’s batch of phase 3 tests of its experimental GI drug etrolizumab has not gone to plan, with “mixed results” highlighting a

This post was originally published on this siteZydus Cadila has completed (PDF) a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase

This post was originally published on this siteAstraZeneca is set to pay Daiichi Sankyo $1 billion to co-develop the antibody-drug conjugate (ADC) DS-1062 outside of Japan. The deal, which

This post was originally published on this siteThe FDA issued its first authorization for pooled testing to Quest Diagnostics last week, in preparation for a new, long-term surveillance phase

This post was originally published on this siteA U.K. biotech has seen its shares skyrocket on new data out from its experimental treatment in hospitalized COVID-19 patients, but it’s too